What disease does dasatinib (Startax) treat?

Dasatinib (Dasatinib) is a targeted therapy used to treat certain types of leukemia, including chronic myelogenous leukemia (CML) and acute lymphoblastic leukemia (ALL).

1.Chronic myelogenous leukemia (CML): CML is a leukemia with abnormal proliferation of bone marrow cells, usually caused by Philadelphia chromosomal abnormalities. This abnormality causes stem cells in the bone marrow to produce an abnormal protein called the BCR-ABL fusion gene, which in turn leads to an abnormal increase in white blood cells. Dasatinib (Startase) blocks the abnormal growth of white blood cells by inhibiting the activity of BCR-ABL protein, thereby reducing the symptoms and progression of CML.

2.Acute lymphoblastic leukemia (ALL): ALL is a type of leukemia that originates in lymphocytes and usually occurs in children and young adults. In some ALL patients, abnormalities in the BCR-ABL fusion gene can also be found, similar to CML. Therefore, dasatinib (Startaxel) is also used to treat some ALL patients, especially those who carry the BCR-ABL fusion gene.

Dasatinib (Startase) is an oral medication that is often given as part of a long-term treatment regimen and is an effective and well-tolerated treatment option for many patients with CML and some ALL. However, dasatinib may also cause some side effects, such as nausea, vomiting, fatigue, rash, etc., so patients should pay close attention and follow their doctor's instructions when using this drug.

Overall,dasatinib is effective in treating CMLIt plays an important role in some ALL patients, helping to control the development of leukemia and improving patients' survival rate and quality of life.